Reflective Case Based Oncology Collective™: Incorporating Novel HER2- Targeted Therapies into Treatment Algorithms Across Metastatic Breast Cancer

Register Now

November 30, 2022 10:00 AM-12:00 PM ET

Overview

Continual rapid advances in the treatment of HER2-positive (HER2+) metastatic breast cancer have expanded therapeutic options and completely transformed the treatment landscape in recent years. Pivotal phase 3 clinical trial data have led to improved overall survival outcomes in later lines of therapy, with approvals for a new antibody-drug conjugate (ADC) and a tyrosine kinase inhibitor (TKI)-based regimen for patients with previously treated HER2+ metastatic disease. Even patients with low HER2 expression have derived benefit with a HER2-targeted ADC—cutting the risk of death in half. Now more than ever, the application of all these new data into clinical practice to optimize treatment sequencing for these patients is imperative.

The Reflective Case-Based Oncology Collective™ combines a core curriculum developed by renowned experts in breast cancer with real-world cases that challenge learners to reflect on the application of the evidence to their own clinical practice, bringing together physicians to collectively consider the ramifications for care of new approaches to treatment and clinical management of metastatic breast cancer.

Benefits of Attending

• Enjoy a morning of direct interaction with world-renowned experts in breast cancer
• Hear varied perspectives on how to manage challenging real-world cases
• Explore how novel HER2-targeted agents are being used to manage patients with HER2-low breast cancer
• Review supportive care measures to manage common and rare adverse events associated with novel HER2-targeted therapies

Target Audience

This educational activity is directed towards community physicians and other healthcare professionals who treat patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Evaluate data from practice-changing clinical trials for patients with HER2+ metastatic breast cancer (MBC) and the impact on evolving treatment standards
• Demonstrate the ability to individualize treatment recommendations for previously treated HER2+ MBC by integrating evidence and practice guidelines with tumor and patient characteristics
• Discuss novel agents and combination regimens undergoing investigation for patients with HER2+ MBC in the context of providing additional clinical trial options for patients
• Implement strategies to monitor and manage HER2-targeted treatment-associated adverse events when caring for patients with HER2+ MBC

Register Now

Reflective Case-Based Oncology Collective™: Incorporating Novel HER2-Targeted Therapies Into Treatment Algorithms Across Metastatic Breast Cancer
Wednesday, November 30, 2022 10:00 AM-12:00 PM ET
Time
10:00 AM	Welcome and Introductions	Sara M. Tolaney, MD, MPH
10:10 AM	Current Treatment Paradigms for HER2+ MBC and Supporting Clinical Evidence Reflective Case-Based Discussion: Patient With HER2+ MBC Progressing on 1st-Line Therapy Patient With HER2+ MBC Progressing on 2nd-Line Therapy Patient With HER2+ Brain Metastases	Sara M. Tolaney, MD, MPH and Michelle E. Melisko, MD
10:50 AM	Recognizing and Managing Adverse Events Associated With HER2-Targeted Therapies Reflective Case-Based Discussion: Patient Who Develops ADC-Related Grade 1 Interstitial Lung Disease Patient Who Develops TKI-Related Diarrhea	Sara M. Tolaney, MD, MPH and Michelle E. Melisko, MD
11:20 AM	New Directions for HER2-Targeted Therapies in HER2-Low MBC Reflective Case-Based Discussion: Patient With HER2-Low MBC	Sara M. Tolaney, MD, MPH and Michelle E. Melisko, MD
11:50 PM	Concluding Remarks	Michelle E. Melisko, MD
12:00 PM	Adjourn

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.